Real-world burden of comorbidities in US patients with psoriatic arthritis

Abstract

ObjectivesWe assessed comorbidities associated with psoriatic arthritis in a broad cohort of US-insured adult patients using the Truven Health Analytics MarketScan Database.MethodsPrevalence and incidence rates were assessed for 28 comorbid conditions among adult patients in the MarketScan database with a diagnosis of psoriatic arthritis and having two or more health claims for psoriatic arthritis between 1 July 2008 and 31 July 2015. Findings were compared with those of a similar, previously published analysis of patients with psoriasis.ResultsAmong a total of 186 552 patients with a diagnosis of psoriatic arthritis, 94 302 had two or more health claims for psoriatic arthritis during the study period and were included in the comorbidity analysis. The prevalence and incidence rates of the most common comorbidities were 47.5% and 35.0% for hyperlipidaemia, respectively; 47.3% and 31.3% for hypertension; 21.2% and 15.4% for depression; 20.2% and 13.5% for type 2 diabetes mellitus; and 16.6% and 12.4% for fibromyalgia. Patients with psoriatic arthritis had notably higher incidence rates of uveitis, fibromyalgia, osteoporosis, Crohn’s disease and non-alcoholic liver disease than patients with psoriasis.ConclusionThis observational retrospective analysis using the MarketScan database provides real-world health claims data on the prevalence and incidence of comorbidities in a large US patient population with psoriatic arthritis. The observed high cardiometabolic comorbidity rates align with those reported in the literature and may help healthcare providers in the comprehensive management of patients with psoriatic arthritis.

IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis

“…Extracutaneous comorbidities are also well-documented in PV, as individuals suffering from severe disease are at high risk of psoriatic arthritis, metabolic syndrome, and atherosclerosis (Burden and Kirby, 2016;Fang et al, 2016;Shah et al, 2017). Therefore, it has been proposed that PV is a systemic disease, manifesting with skin, joint, and vascular inflammation (Davidovici et al, 2010;Reich, 2012).…”

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review

“…In this review, we discuss the prevalence of type 2 diabetes in patients with PsA. DM is among the most common metabolic disorders, with majority of patients (90-95%) affected by type 2 DM [12]. Few studies investigate the association between type 1 DM and other immune-mediated diseases including PsA, but they do not find any association [13].…”

Clinical and epidemiological characterization of psoriasis and psoriatic arthritis in a multidisciplinary assessment model

“…Is important to mention that our center has two years since it was opened so we expected to admit more patients and it is expected that the rates that we showed could change. This was the first study in Mexico that evaluated comorbidities, this is very important because there are other authors that have showed that comorbidities in psoriatic arthritis patients are an important burden in the health system [8,10]. Shah K et al [10], showed a prevalence rate of 35% of dyslipidemia, 31% of hypertension, 15% of depression and 13% of diabetes mellitus vs. 22, 31, 15 and 13% respectively.…”